Berit Lindholm is VP Operations Sweden and Managing Director at Fresenius Kabi AB. At Fresenius Kabi AB she is responsible for the plants in Sweden. She has founded experience in leading in the pharma industry through her work at Bluefish Pharmaceuticals as COO and CEO as well at being CEO and President at Swedish Institute of Quality and working as Head of Planning at AstraZeneca. Through her work she has founded technical and pharmaceutical knowledge in global context.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. In the field of biosimilars, we develop products with a focus on oncology and autoimmune diseases. Our products and services are used to help care for critically and chronically ill patients. With our corporate philosophy of "caring for life"​, we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. Fresenius Kabi employs more than 37,800 people worldwide. In 2018 the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group. Fresenius Kabi is a global leader in our business segments. We offer employees of diverse cultures and backgrounds a wide range of fulfilling and challenging career and personal growth opportunities, both domestically and internationally. We work together in a spirit of partnership, personal commitment and integrity to create value. We offer: • world-class, dedicated teams • an open-minded, creative, can-do culture • a variety of opportunities to grow with the business • the chance to make a difference in patients’ quality of life